Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

abstract：PURPOSE:To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), in peripheral blood mononuclear cells (PBMCs). METHODS:Patients with advanced pancreatic cancer who had not received chemotherapy and had acceptable organ function were el...

journal_title：Cancer chemotherapy and pharmacology

authors： Xiong HQ,Plunkett W,Wolff R,Du M,Lenzi R,Abbruzzese JL

更新日期：2005-06-01 00:00:00

abstract：:Patients with carcinoid syndrome usually die from carcinomatosis, rather than the pharmacological effects of the tumour. Functioning carcinoid tumours are resistant to radiotherapy. Twenty-four different cytotoxic drugs or combinations have been used to treat the carcinoid syndrome, but only actinomycin D, cyclophosph...

journal_title：Cancer chemotherapy and pharmacology

authors： Harris AL

更新日期：1981-01-01 00:00:00

abstract：:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplant...

journal_title：Cancer chemotherapy and pharmacology

authors： Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

更新日期：1996-01-01 00:00:00

abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...

journal_title：Cancer chemotherapy and pharmacology

authors： Zylicz Z,Wagener DJ,Fernandez del Moral P,van Rennes H,Wessels JM,Winograd B,van der Kleijn E,Vree TB,van Haelst U,van den Broek LA

更新日期：1987-01-01 00:00:00

abstract：:The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:O(6)-benzylguanine (BG) is a pseudosubstrate inactivator of the DNA repair protein O(6)- alkylguanine-DNA alkyltransferase (AGT) that has entered clinical trials as a potentiator of the antitumor effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). This study was designed to evaluate potential mechanisms of B...

journal_title：Cancer chemotherapy and pharmacology

authors： Phillips WP Jr,Gerson SL

更新日期：1999-01-01 00:00:00

abstract：:Despite its rapid enzymatic inactivation and therefore limited activity in vivo, Gemcitabine is the standard drug for pancreatic cancer treatment. To protect the drug, and achieve passive tumor targeting, we developed a liposomal formulation of Gemcitabine, GemLip (Ø: 36 nm: 47% entrapment). Its anti-tumoral activity ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bornmann C,Graeser R,Esser N,Ziroli V,Jantscheff P,Keck T,Unger C,Hopt UT,Adam U,Schaechtele C,Massing U,von Dobschuetz E

更新日期：2008-03-01 00:00:00

abstract：PURPOSE:Pemetrexed, a multi-targeted antifolate that disrupts synthesis of both purines and pyrimidines, is approved for use in malignant pleural mesothelioma and non-small cell lung cancer. Pemetrexed is currently being evaluated for anti-tumor activity in a variety of solid and central nervous system tumors. We studi...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Reid JM,Thompson PA,Ames MM,McGovern RM,McGuffey L,Nuchtern J,Dauser R,Blaney SM

更新日期：2007-03-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bose P,Perkins EB,Honeycut C,Wellons MD,Stefan T,Jacobberger JW,Kontopodis E,Beumer JH,Egorin MJ,Imamura CK,Douglas Figg W Sr,Karp JE,Koc ON,Cooper BW,Luger SM,Colevas AD,Roberts JD,Grant S

更新日期：2012-06-01 00:00:00

abstract：:Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and -resistant L1210 tumor-bearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slight...

journal_title：Cancer chemotherapy and pharmacology

authors： Institóris E,Szikla K,Otvös L,Gál F

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The potential use of combined therapy is under intensive study including the association between classical cytotoxic and genes encoding toxic proteins which enhanced the antitumour activity. The main aim of this work was to evaluate whether the gef gene, a suicide gene which has a demonstrated antiproliferative...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados J,Melguizo C,Rama AR,Ortiz R,Segura A,Boulaiz H,Vélez C,Caba O,Ramos JL,Aránega A

更新日期：2010-05-01 00:00:00

abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

journal_title：Cancer chemotherapy and pharmacology

authors： He G,Xie X,Siddik ZH

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:Standardized enumeration of CEC counts is required to minimize variability and allow cross-studies comparisons. The purpose of this paper is to identify CEC threshold proposal, by CellSearch system, for determining response to bevacizumab-based chemotherapy in metastatic colorectal cancer. METHODS:From July 20...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsusaka S,Suenaga M,Mishima Y,Takagi K,Terui Y,Mizunuma N,Hatake K

更新日期：2011-09-01 00:00:00

abstract：:Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, bu...

journal_title：Cancer chemotherapy and pharmacology

authors： Breccia M,Cilloni D,Cannella L,Stefanizzi C,Tafuri A,Fama A,Santopietro M,Saglio G,Alimena G

更新日期：2009-05-01 00:00:00

abstract：:Targeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodi...

journal_title：Cancer chemotherapy and pharmacology

authors： Epstein RJ,Leung TW

更新日期：2008-11-01 00:00:00

abstract：PURPOSE:Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. This two-part, open-label Phase I study was, therefore, carried out to det...

journal_title：Cancer chemotherapy and pharmacology

authors： Yuan P,Shentu J,Xu J,Burke W,Hsu K,Learoyd M,Zhu M,Xu B

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

journal_title：Cancer chemotherapy and pharmacology

authors： Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical researc...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Yuan Z,Zhang Y,Cui Z,Li Y,Hou J,Liu X,Liu Z,Shi R,Tian Q,Wang J,Wang L

更新日期：2021-01-01 00:00:00

abstract：:KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were com...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi E,Okabe M,Kono M,Arai H,Kasai M,Gomi K,Lee JH,Inaba M,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：:The pharmacokinetics of soluble oral prednisolone were studied during induction therapy in six children with acute lymphoblastic leukaemia. There was a three- to four-fold variation in the pharmacokinetics of total and free prednisolone. For total prednisolone, the mean elimination half-life was relatively short (1.37...

journal_title：Cancer chemotherapy and pharmacology

authors： Choonara I,Wheeldon J,Rayner P,Blackburn M,Lewis I

更新日期：1989-01-01 00:00:00

abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang K,Stark FS,Schlothauer T,Lahr A,Cosson V,Zhi J,Habben K,Tessier J,Schick E,Staack RF,Krieter O

更新日期：2017-04-01 00:00:00

abstract：PURPOSE:To investigate the activity of combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin in patients with metastatic urothelial cancer. METHODS:A group of 29 patients were treated with 2000 mg/m2 ifosfamide, 750 mg/m2 5-fluorouracil, 100 mg/m2 etoposide and 20 mg/m2 cisplatin. All four ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukui I,Yonese J,Tsukamoto T,Yoshida T,Kim T,Tohma T,Ishiwata D

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:To explore the protective effect of KLF4 against cytotoxicity induced by cisplatin and its possible mechanisms. METHODS:The expression levels of KLF4 were detected by RT-PCR and western blot in cancer stem-like cells derived from hepatocarcinoma (T3A-A3) and the hepatocarcinoma cell line HepG2. KLF4 was knocke...

journal_title：Cancer chemotherapy and pharmacology

authors： Jia Y,Zhang W,Liu H,Peng L,Yang Z,Lou J

更新日期：2012-02-01 00:00:00

abstract：PURPOSE:Studies were conducted on oryzalin (3,5-dinitro-N,N-di(n-propyl)sulfanilamide), a widely used dinitroaniline sulfonamide herbicide, which was identified from plant extracts as an inhibitor of mitogen- and growth factor-mediated intracellular free Ca2+ ([Ca2+]i) signalling in mammalian cells. METHODS AND RESULT...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Gallegos A,Abraham RT,Ashendel CL,Zalkow LH,Dorr R,Dvorakova K,Salmon S,Harrison S,Worzalla J

更新日期：1997-01-01 00:00:00

abstract：:For years, MDA-MB-435 cells have been widely but erroneously used as breast cancer cells with aggressive behaviour. Recent data show that they are in fact melanoma cells. However, many scientists are still unaware of this "new" identity. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lacroix M

更新日期：2009-02-01 00:00:00

abstract：:The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to asse...

journal_title：Cancer chemotherapy and pharmacology

authors： Pauwels O,Kiss R

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide. PATIENTS AND METHODS:Patients were stratified according to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados MD,Yung WK,Wen PY,Junck L,Cloughesy T,Fink K,Chang S,Robins HI,Dancey J,Kuhn J

更新日期：2008-05-01 00:00:00

abstract：:P388 murine leukemic cells lines which were resistant (P388R) or sensitive (P388S) to adriamycin (adr) were used to evaluate the potential utility of in vitro clonogenic assays for detecting and quantitating the number of adr-resistant cells present in a cell mixture. The progeny of P388S cells that had been exposed f...

journal_title：Cancer chemotherapy and pharmacology

authors： Dong GW,Preisler HD,Priore R

更新日期：1984-01-01 00:00:00